AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Innovative Platform | AbCellera's tech-enabled antibody discovery platform shows promise in drug development, validated through COVID-19 treatments and strategic partnerships. |
Financial Strength | With $1 billion in liquidity, AbCellera is well-positioned for extended operations and strategic investments, despite recent downward estimate revisions. |
Explore Partnerships | Collaborations with Biogen and Viking/ArrowMark highlight AbCellera's potential for long-term revenue growth and expanded therapeutic applications. |
Future Prospects | Analyst targets range from $7 to $12, reflecting optimism about AbCellera's internal pipeline development and manufacturing capabilities amid industry changes. |
Metrics to compare | ABCL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABCLPeersSector | |
---|---|---|---|---|
P/E Ratio | −7.8x | −3.1x | −0.6x | |
PEG Ratio | 1.35 | 0.00 | 0.00 | |
Price/Book | 1.3x | 0.7x | 2.6x | |
Price / LTM Sales | 39.4x | 1.7x | 3.3x | |
Upside (Analyst Target) | 112.8% | 50.5% | 39.0% | |
Fair Value Upside | Unlock | 34.4% | 4.9% | Unlock |